1 Market Overview

1.1 Product Overview and Scope of Gene Therapy On Cardiovascular Disease

1.2 Classification of Gene Therapy On Cardiovascular Disease by Type

1.2.1 Overview: Global Gene Therapy On Cardiovascular Disease Market Size by Type: 2017 Versus 2021 Versus 2028

1.2.2 Global Gene Therapy On Cardiovascular Disease Revenue Market Share by Type in 2021

1.2.3 Viral Gene Therapy

1.2.4 Non-Viral Gene Therapy

1.3 Global Gene Therapy On Cardiovascular Disease Market by Application

1.3.1 Overview: Global Gene Therapy On Cardiovascular Disease Market Size by Application: 2017 Versus 2021 Versus 2028

1.3.2 Heart Disease

1.3.3 Vascular Disease

1.4 Global Gene Therapy On Cardiovascular Disease Market Size & Forecast

1.5 Global Gene Therapy On Cardiovascular Disease Market Size and Forecast by Region

1.5.1 Global Gene Therapy On Cardiovascular Disease Market Size by Region: 2017 VS 2021 VS 2028

1.5.2 Global Gene Therapy On Cardiovascular Disease Market Size by Region, (2017-2022)

1.5.3 North America Gene Therapy On Cardiovascular Disease Market Size and Prospect (2017-2028)

1.5.4 Europe Gene Therapy On Cardiovascular Disease Market Size and Prospect (2017-2028)

1.5.5 Asia-Pacific Gene Therapy On Cardiovascular Disease Market Size and Prospect (2017-2028)

1.5.6 South America Gene Therapy On Cardiovascular Disease Market Size and Prospect (2017-2028)

1.5.7 Middle East and Africa Gene Therapy On Cardiovascular Disease Market Size and Prospect (2017-2028)

1.6 Market Drivers, Restraints and Trends

1.6.1 Gene Therapy On Cardiovascular Disease Market Drivers

1.6.2 Gene Therapy On Cardiovascular Disease Market Restraints

1.6.3 Gene Therapy On Cardiovascular Disease Trends Analysis

2 Company Profiles

2.1 Biogen

2.1.1 Biogen Details

2.1.2 Biogen Major Business

2.1.3 Biogen Gene Therapy On Cardiovascular Disease Product and Solutions

2.1.4 Biogen Gene Therapy On Cardiovascular Disease Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.1.5 Biogen Recent Developments and Future Plans

2.2 Novartis

2.2.1 Novartis Details

2.2.2 Novartis Major Business

2.2.3 Novartis Gene Therapy On Cardiovascular Disease Product and Solutions

2.2.4 Novartis Gene Therapy On Cardiovascular Disease Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.2.5 Novartis Recent Developments and Future Plans

2.3 Gilead Sciences

2.3.1 Gilead Sciences Details

2.3.2 Gilead Sciences Major Business

2.3.3 Gilead Sciences Gene Therapy On Cardiovascular Disease Product and Solutions

2.3.4 Gilead Sciences Gene Therapy On Cardiovascular Disease Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.3.5 Gilead Sciences Recent Developments and Future Plans

2.4 Sarepta Therapeutics

2.4.1 Sarepta Therapeutics Details

2.4.2 Sarepta Therapeutics Major Business

2.4.3 Sarepta Therapeutics Gene Therapy On Cardiovascular Disease Product and Solutions

2.4.4 Sarepta Therapeutics Gene Therapy On Cardiovascular Disease Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.4.5 Sarepta Therapeutics Recent Developments and Future Plans

2.5 Alnylam Pharmaceuticals

2.5.1 Alnylam Pharmaceuticals Details

2.5.2 Alnylam Pharmaceuticals Major Business

2.5.3 Alnylam Pharmaceuticals Gene Therapy On Cardiovascular Disease Product and Solutions

2.5.4 Alnylam Pharmaceuticals Gene Therapy On Cardiovascular Disease Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.5.5 Alnylam Pharmaceuticals Recent Developments and Future Plans

2.6 Amgen

2.6.1 Amgen Details

2.6.2 Amgen Major Business

2.6.3 Amgen Gene Therapy On Cardiovascular Disease Product and Solutions

2.6.4 Amgen Gene Therapy On Cardiovascular Disease Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.6.5 Amgen Recent Developments and Future Plans

2.7 Spark Therapeutics

2.7.1 Spark Therapeutics Details

2.7.2 Spark Therapeutics Major Business

2.7.3 Spark Therapeutics Gene Therapy On Cardiovascular Disease Product and Solutions

2.7.4 Spark Therapeutics Gene Therapy On Cardiovascular Disease Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.7.5 Spark Therapeutics Recent Developments and Future Plans

2.8 Akcea Therapeutics

2.8.1 Akcea Therapeutics Details

2.8.2 Akcea Therapeutics Major Business

2.8.3 Akcea Therapeutics Gene Therapy On Cardiovascular Disease Product and Solutions

2.8.4 Akcea Therapeutics Gene Therapy On Cardiovascular Disease Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.8.5 Akcea Therapeutics Recent Developments and Future Plans

2.9 bluebird bio

2.9.1 bluebird bio Details

2.9.2 bluebird bio Major Business

2.9.3 bluebird bio Gene Therapy On Cardiovascular Disease Product and Solutions

2.9.4 bluebird bio Gene Therapy On Cardiovascular Disease Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.9.5 bluebird bio Recent Developments and Future Plans

2.10 Sunway Biotech

2.10.1 Sunway Biotech Details

2.10.2 Sunway Biotech Major Business

2.10.3 Sunway Biotech Gene Therapy On Cardiovascular Disease Product and Solutions

2.10.4 Sunway Biotech Gene Therapy On Cardiovascular Disease Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.10.5 Sunway Biotech Recent Developments and Future Plans

2.11 SIBIONO

2.11.1 SIBIONO Details

2.11.2 SIBIONO Major Business

2.11.3 SIBIONO Gene Therapy On Cardiovascular Disease Product and Solutions

2.11.4 SIBIONO Gene Therapy On Cardiovascular Disease Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.11.5 SIBIONO Recent Developments and Future Plans

2.12 AnGes

2.12.1 AnGes Details

2.12.2 AnGes Major Business

2.12.3 AnGes Gene Therapy On Cardiovascular Disease Product and Solutions

2.12.4 AnGes Gene Therapy On Cardiovascular Disease Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.12.5 AnGes Recent Developments and Future Plans

2.13 Orchard Therapeutics

2.13.1 Orchard Therapeutics Details

2.13.2 Orchard Therapeutics Major Business

2.13.3 Orchard Therapeutics Gene Therapy On Cardiovascular Disease Product and Solutions

2.13.4 Orchard Therapeutics Gene Therapy On Cardiovascular Disease Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.13.5 Orchard Therapeutics Recent Developments and Future Plans

2.14 Human Stem Cells Institute

2.14.1 Human Stem Cells Institute Details

2.14.2 Human Stem Cells Institute Major Business

2.14.3 Human Stem Cells Institute Gene Therapy On Cardiovascular Disease Product and Solutions

2.14.4 Human Stem Cells Institute Gene Therapy On Cardiovascular Disease Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.14.5 Human Stem Cells Institute Recent Developments and Future Plans

3 Market Competition, by Players

3.1 Global Gene Therapy On Cardiovascular Disease Revenue and Share by Players (2019, 2020, 2021, and 2022)

3.2 Market Concentration Rate

3.2.1 Top 3 Gene Therapy On Cardiovascular Disease Players Market Share in 2021

3.2.2 Top 10 Gene Therapy On Cardiovascular Disease Players Market Share in 2021

3.2.3 Market Competition Trend

3.3 Gene Therapy On Cardiovascular Disease Players Head Office, Products and Services Provided

3.4 Gene Therapy On Cardiovascular Disease Mergers & Acquisitions

3.5 Gene Therapy On Cardiovascular Disease New Entrants and Expansion Plans

4 Market Size Segment by Type

4.1 Global Gene Therapy On Cardiovascular Disease Revenue and Market Share by Type (2017-2022)

4.2 Global Gene Therapy On Cardiovascular Disease Market Forecast by Type (2023-2028)

5 Market Size Segment by Application

5.1 Global Gene Therapy On Cardiovascular Disease Revenue Market Share by Application (2017-2022)

5.2 Global Gene Therapy On Cardiovascular Disease Market Forecast by Application (2023-2028)

6 North America by Country, by Type, and by Application

6.1 North America Gene Therapy On Cardiovascular Disease Revenue by Type (2017-2028)

6.2 North America Gene Therapy On Cardiovascular Disease Revenue by Application (2017-2028)

6.3 North America Gene Therapy On Cardiovascular Disease Market Size by Country

6.3.1 North America Gene Therapy On Cardiovascular Disease Revenue by Country (2017-2028)

6.3.2 United States Gene Therapy On Cardiovascular Disease Market Size and Forecast (2017-2028)

6.3.3 Canada Gene Therapy On Cardiovascular Disease Market Size and Forecast (2017-2028)

6.3.4 Mexico Gene Therapy On Cardiovascular Disease Market Size and Forecast (2017-2028)

7 Europe by Country, by Type, and by Application

7.1 Europe Gene Therapy On Cardiovascular Disease Revenue by Type (2017-2028)

7.2 Europe Gene Therapy On Cardiovascular Disease Revenue by Application (2017-2028)

7.3 Europe Gene Therapy On Cardiovascular Disease Market Size by Country

7.3.1 Europe Gene Therapy On Cardiovascular Disease Revenue by Country (2017-2028)

7.3.2 Germany Gene Therapy On Cardiovascular Disease Market Size and Forecast (2017-2028)

7.3.3 France Gene Therapy On Cardiovascular Disease Market Size and Forecast (2017-2028)

7.3.4 United Kingdom Gene Therapy On Cardiovascular Disease Market Size and Forecast (2017-2028)

7.3.5 Russia Gene Therapy On Cardiovascular Disease Market Size and Forecast (2017-2028)

7.3.6 Italy Gene Therapy On Cardiovascular Disease Market Size and Forecast (2017-2028)

8 Asia-Pacific by Region, by Type, and by Application

8.1 Asia-Pacific Gene Therapy On Cardiovascular Disease Revenue by Type (2017-2028)

8.2 Asia-Pacific Gene Therapy On Cardiovascular Disease Revenue by Application (2017-2028)

8.3 Asia-Pacific Gene Therapy On Cardiovascular Disease Market Size by Region

8.3.1 Asia-Pacific Gene Therapy On Cardiovascular Disease Revenue by Region (2017-2028)

8.3.2 China Gene Therapy On Cardiovascular Disease Market Size and Forecast (2017-2028)

8.3.3 Japan Gene Therapy On Cardiovascular Disease Market Size and Forecast (2017-2028)

8.3.4 South Korea Gene Therapy On Cardiovascular Disease Market Size and Forecast (2017-2028)

8.3.5 India Gene Therapy On Cardiovascular Disease Market Size and Forecast (2017-2028)

8.3.6 Southeast Asia Gene Therapy On Cardiovascular Disease Market Size and Forecast (2017-2028)

8.3.7 Australia Gene Therapy On Cardiovascular Disease Market Size and Forecast (2017-2028)

9 South America by Country, by Type, and by Application

9.1 South America Gene Therapy On Cardiovascular Disease Revenue by Type (2017-2028)

9.2 South America Gene Therapy On Cardiovascular Disease Revenue by Application (2017-2028)

9.3 South America Gene Therapy On Cardiovascular Disease Market Size by Country

9.3.1 South America Gene Therapy On Cardiovascular Disease Revenue by Country (2017-2028)

9.3.2 Brazil Gene Therapy On Cardiovascular Disease Market Size and Forecast (2017-2028)

9.3.3 Argentina Gene Therapy On Cardiovascular Disease Market Size and Forecast (2017-2028)

10 Middle East & Africa by Country, by Type, and by Application

10.1 Middle East & Africa Gene Therapy On Cardiovascular Disease Revenue by Type (2017-2028)

10.2 Middle East & Africa Gene Therapy On Cardiovascular Disease Revenue by Application (2017-2028)

10.3 Middle East & Africa Gene Therapy On Cardiovascular Disease Market Size by Country

10.3.1 Middle East & Africa Gene Therapy On Cardiovascular Disease Revenue by Country (2017-2028)

10.3.2 Turkey Gene Therapy On Cardiovascular Disease Market Size and Forecast (2017-2028)

10.3.3 Saudi Arabia Gene Therapy On Cardiovascular Disease Market Size and Forecast (2017-2028)

10.3.4 UAE Gene Therapy On Cardiovascular Disease Market Size and Forecast (2017-2028)

11 Research Findings and Conclusion

12 Appendix

12.1 Methodology

12.2 Research Process and Data Source

12.3 Disclaimer

List of Tables

Table 1. Global Gene Therapy On Cardiovascular Disease Revenue by Type, (USD Million), 2017 VS 2021 VS 2028

Table 2. Global Gene Therapy On Cardiovascular Disease Revenue by Application, (USD Million), 2017 VS 2021 VS 2028

Table 3. Global Market Gene Therapy On Cardiovascular Disease Revenue (Million USD) Comparison by Region (2017 VS 2021 VS 2028)

Table 4. Global Gene Therapy On Cardiovascular Disease Revenue (USD Million) by Region (2017-2022)

Table 5. Global Gene Therapy On Cardiovascular Disease Revenue Market Share by Region (2023-2028)

Table 6. Biogen Corporate Information, Head Office, and Major Competitors

Table 7. Biogen Major Business

Table 8. Biogen Gene Therapy On Cardiovascular Disease Product and Solutions

Table 9. Biogen Gene Therapy On Cardiovascular Disease Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 10. Novartis Corporate Information, Head Office, and Major Competitors

Table 11. Novartis Major Business

Table 12. Novartis Gene Therapy On Cardiovascular Disease Product and Solutions

Table 13. Novartis Gene Therapy On Cardiovascular Disease Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 14. Gilead Sciences Corporate Information, Head Office, and Major Competitors

Table 15. Gilead Sciences Major Business

Table 16. Gilead Sciences Gene Therapy On Cardiovascular Disease Product and Solutions

Table 17. Gilead Sciences Gene Therapy On Cardiovascular Disease Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 18. Sarepta Therapeutics Corporate Information, Head Office, and Major Competitors

Table 19. Sarepta Therapeutics Major Business

Table 20. Sarepta Therapeutics Gene Therapy On Cardiovascular Disease Product and Solutions

Table 21. Sarepta Therapeutics Gene Therapy On Cardiovascular Disease Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 22. Alnylam Pharmaceuticals Corporate Information, Head Office, and Major Competitors

Table 23. Alnylam Pharmaceuticals Major Business

Table 24. Alnylam Pharmaceuticals Gene Therapy On Cardiovascular Disease Product and Solutions

Table 25. Alnylam Pharmaceuticals Gene Therapy On Cardiovascular Disease Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 26. Amgen Corporate Information, Head Office, and Major Competitors

Table 27. Amgen Major Business

Table 28. Amgen Gene Therapy On Cardiovascular Disease Product and Solutions

Table 29. Amgen Gene Therapy On Cardiovascular Disease Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 30. Spark Therapeutics Corporate Information, Head Office, and Major Competitors

Table 31. Spark Therapeutics Major Business

Table 32. Spark Therapeutics Gene Therapy On Cardiovascular Disease Product and Solutions

Table 33. Spark Therapeutics Gene Therapy On Cardiovascular Disease Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 34. Akcea Therapeutics Corporate Information, Head Office, and Major Competitors

Table 35. Akcea Therapeutics Major Business

Table 36. Akcea Therapeutics Gene Therapy On Cardiovascular Disease Product and Solutions

Table 37. Akcea Therapeutics Gene Therapy On Cardiovascular Disease Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 38. bluebird bio Corporate Information, Head Office, and Major Competitors

Table 39. bluebird bio Major Business

Table 40. bluebird bio Gene Therapy On Cardiovascular Disease Product and Solutions

Table 41. bluebird bio Gene Therapy On Cardiovascular Disease Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 42. Sunway Biotech Corporate Information, Head Office, and Major Competitors

Table 43. Sunway Biotech Major Business

Table 44. Sunway Biotech Gene Therapy On Cardiovascular Disease Product and Solutions

Table 45. Sunway Biotech Gene Therapy On Cardiovascular Disease Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 46. SIBIONO Corporate Information, Head Office, and Major Competitors

Table 47. SIBIONO Major Business

Table 48. SIBIONO Gene Therapy On Cardiovascular Disease Product and Solutions

Table 49. SIBIONO Gene Therapy On Cardiovascular Disease Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 50. AnGes Corporate Information, Head Office, and Major Competitors

Table 51. AnGes Major Business

Table 52. AnGes Gene Therapy On Cardiovascular Disease Product and Solutions

Table 53. AnGes Gene Therapy On Cardiovascular Disease Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 54. Orchard Therapeutics Corporate Information, Head Office, and Major Competitors

Table 55. Orchard Therapeutics Major Business

Table 56. Orchard Therapeutics Gene Therapy On Cardiovascular Disease Product and Solutions

Table 57. Orchard Therapeutics Gene Therapy On Cardiovascular Disease Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 58. Human Stem Cells Institute Corporate Information, Head Office, and Major Competitors

Table 59. Human Stem Cells Institute Major Business

Table 60. Human Stem Cells Institute Gene Therapy On Cardiovascular Disease Product and Solutions

Table 61. Human Stem Cells Institute Gene Therapy On Cardiovascular Disease Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 62. Global Gene Therapy On Cardiovascular Disease Revenue (USD Million) by Players (2019, 2020, 2021, and 2022)

Table 63. Global Gene Therapy On Cardiovascular Disease Revenue Share by Players (2019, 2020, 2021, and 2022)

Table 64. Breakdown of Gene Therapy On Cardiovascular Disease by Company Type (Tier 1, Tier 2 and Tier 3)

Table 65. Gene Therapy On Cardiovascular Disease Players Head Office, Products and Services Provided

Table 66. Gene Therapy On Cardiovascular Disease Mergers & Acquisitions in the Past Five Years

Table 67. Gene Therapy On Cardiovascular Disease New Entrants and Expansion Plans

Table 68. Global Gene Therapy On Cardiovascular Disease Revenue (USD Million) by Type (2017-2022)

Table 69. Global Gene Therapy On Cardiovascular Disease Revenue Share by Type (2017-2022)

Table 70. Global Gene Therapy On Cardiovascular Disease Revenue Forecast by Type (2023-2028)

Table 71. Global Gene Therapy On Cardiovascular Disease Revenue by Application (2017-2022)

Table 72. Global Gene Therapy On Cardiovascular Disease Revenue Forecast by Application (2023-2028)

Table 73. North America Gene Therapy On Cardiovascular Disease Revenue by Type (2017-2022) & (USD Million)

Table 74. North America Gene Therapy On Cardiovascular Disease Revenue by Type (2023-2028) & (USD Million)

Table 75. North America Gene Therapy On Cardiovascular Disease Revenue by Application (2017-2022) & (USD Million)

Table 76. North America Gene Therapy On Cardiovascular Disease Revenue by Application (2023-2028) & (USD Million)

Table 77. North America Gene Therapy On Cardiovascular Disease Revenue by Country (2017-2022) & (USD Million)

Table 78. North America Gene Therapy On Cardiovascular Disease Revenue by Country (2023-2028) & (USD Million)

Table 79. Europe Gene Therapy On Cardiovascular Disease Revenue by Type (2017-2022) & (USD Million)

Table 80. Europe Gene Therapy On Cardiovascular Disease Revenue by Type (2023-2028) & (USD Million)

Table 81. Europe Gene Therapy On Cardiovascular Disease Revenue by Application (2017-2022) & (USD Million)

Table 82. Europe Gene Therapy On Cardiovascular Disease Revenue by Application (2023-2028) & (USD Million)

Table 83. Europe Gene Therapy On Cardiovascular Disease Revenue by Country (2017-2022) & (USD Million)

Table 84. Europe Gene Therapy On Cardiovascular Disease Revenue by Country (2023-2028) & (USD Million)

Table 85. Asia-Pacific Gene Therapy On Cardiovascular Disease Revenue by Type (2017-2022) & (USD Million)

Table 86. Asia-Pacific Gene Therapy On Cardiovascular Disease Revenue by Type (2023-2028) & (USD Million)

Table 87. Asia-Pacific Gene Therapy On Cardiovascular Disease Revenue by Application (2017-2022) & (USD Million)

Table 88. Asia-Pacific Gene Therapy On Cardiovascular Disease Revenue by Application (2023-2028) & (USD Million)

Table 89. Asia-Pacific Gene Therapy On Cardiovascular Disease Revenue by Region (2017-2022) & (USD Million)

Table 90. Asia-Pacific Gene Therapy On Cardiovascular Disease Revenue by Region (2023-2028) & (USD Million)

Table 91. South America Gene Therapy On Cardiovascular Disease Revenue by Type (2017-2022) & (USD Million)

Table 92. South America Gene Therapy On Cardiovascular Disease Revenue by Type (2023-2028) & (USD Million)

Table 93. South America Gene Therapy On Cardiovascular Disease Revenue by Application (2017-2022) & (USD Million)

Table 94. South America Gene Therapy On Cardiovascular Disease Revenue by Application (2023-2028) & (USD Million)

Table 95. South America Gene Therapy On Cardiovascular Disease Revenue by Country (2017-2022) & (USD Million)

Table 96. South America Gene Therapy On Cardiovascular Disease Revenue by Country (2023-2028) & (USD Million)

Table 97. Middle East & Africa Gene Therapy On Cardiovascular Disease Revenue by Type (2017-2022) & (USD Million)

Table 98. Middle East & Africa Gene Therapy On Cardiovascular Disease Revenue by Type (2023-2028) & (USD Million)

Table 99. Middle East & Africa Gene Therapy On Cardiovascular Disease Revenue by Application (2017-2022) & (USD Million)

Table 100. Middle East & Africa Gene Therapy On Cardiovascular Disease Revenue by Application (2023-2028) & (USD Million)

Table 101. Middle East & Africa Gene Therapy On Cardiovascular Disease Revenue by Country (2017-2022) & (USD Million)

Table 102. Middle East & Africa Gene Therapy On Cardiovascular Disease Revenue by Country (2023-2028) & (USD Million)

List of Figures

Figure 1. Gene Therapy On Cardiovascular Disease Picture

Figure 2. Global Gene Therapy On Cardiovascular Disease Revenue Market Share by Type in 2021

Figure 3. Viral Gene Therapy

Figure 4. Non-Viral Gene Therapy

Figure 5. Gene Therapy On Cardiovascular Disease Revenue Market Share by Application in 2021

Figure 6. Heart Disease Picture

Figure 7. Vascular Disease Picture

Figure 8. Global Gene Therapy On Cardiovascular Disease Market Size, (USD Million): 2017 VS 2021 VS 2028

Figure 9. Global Gene Therapy On Cardiovascular Disease Revenue and Forecast (2017-2028) & (USD Million)

Figure 10. Global Gene Therapy On Cardiovascular Disease Revenue Market Share by Region (2017-2028)

Figure 11. Global Gene Therapy On Cardiovascular Disease Revenue Market Share by Region in 2021

Figure 12. North America Gene Therapy On Cardiovascular Disease Revenue (USD Million) and Growth Rate (2017-2028)

Figure 13. Europe Gene Therapy On Cardiovascular Disease Revenue (USD Million) and Growth Rate (2017-2028)

Figure 14. Asia-Pacific Gene Therapy On Cardiovascular Disease Revenue (USD Million) and Growth Rate (2017-2028)

Figure 15. South America Gene Therapy On Cardiovascular Disease Revenue (USD Million) and Growth Rate (2017-2028)

Figure 16. Middle East and Africa Gene Therapy On Cardiovascular Disease Revenue (USD Million) and Growth Rate (2017-2028)

Figure 17. Gene Therapy On Cardiovascular Disease Market Drivers

Figure 18. Gene Therapy On Cardiovascular Disease Market Restraints

Figure 19. Gene Therapy On Cardiovascular Disease Market Trends

Figure 20. Biogen Recent Developments and Future Plans

Figure 21. Novartis Recent Developments and Future Plans

Figure 22. Gilead Sciences Recent Developments and Future Plans

Figure 23. Sarepta Therapeutics Recent Developments and Future Plans

Figure 24. Alnylam Pharmaceuticals Recent Developments and Future Plans

Figure 25. Amgen Recent Developments and Future Plans

Figure 26. Spark Therapeutics Recent Developments and Future Plans

Figure 27. Akcea Therapeutics Recent Developments and Future Plans

Figure 28. bluebird bio Recent Developments and Future Plans

Figure 29. Sunway Biotech Recent Developments and Future Plans

Figure 30. SIBIONO Recent Developments and Future Plans

Figure 31. AnGes Recent Developments and Future Plans

Figure 32. Orchard Therapeutics Recent Developments and Future Plans

Figure 33. Human Stem Cells Institute Recent Developments and Future Plans

Figure 34. Global Gene Therapy On Cardiovascular Disease Revenue Share by Players in 2021

Figure 35. Gene Therapy On Cardiovascular Disease Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2021

Figure 36. Global Top 3 Players Gene Therapy On Cardiovascular Disease Revenue Market Share in 2021

Figure 37. Global Top 10 Players Gene Therapy On Cardiovascular Disease Revenue Market Share in 2021

Figure 38. Key Players Market Share Trend (Top 3 Market Share: 2020 VS 2021 VS 2022)

Figure 39. Global Gene Therapy On Cardiovascular Disease Revenue Share by Type in 2021

Figure 40. Global Gene Therapy On Cardiovascular Disease Market Share Forecast by Type (2023-2028)

Figure 41. Global Gene Therapy On Cardiovascular Disease Revenue Share by Application in 2021

Figure 42. Global Gene Therapy On Cardiovascular Disease Market Share Forecast by Application (2023-2028)

Figure 43. North America Gene Therapy On Cardiovascular Disease Sales Market Share by Type (2017-2028)

Figure 44. North America Gene Therapy On Cardiovascular Disease Sales Market Share by Application (2017-2028)

Figure 45. North America Gene Therapy On Cardiovascular Disease Revenue Market Share by Country (2017-2028)

Figure 46. United States Gene Therapy On Cardiovascular Disease Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 47. Canada Gene Therapy On Cardiovascular Disease Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 48. Mexico Gene Therapy On Cardiovascular Disease Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 49. Europe Gene Therapy On Cardiovascular Disease Sales Market Share by Type (2017-2028)

Figure 50. Europe Gene Therapy On Cardiovascular Disease Sales Market Share by Application (2017-2028)

Figure 51. Europe Gene Therapy On Cardiovascular Disease Revenue Market Share by Country (2017-2028)

Figure 52. Germany Gene Therapy On Cardiovascular Disease Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 53. France Gene Therapy On Cardiovascular Disease Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 54. United Kingdom Gene Therapy On Cardiovascular Disease Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 55. Russia Gene Therapy On Cardiovascular Disease Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 56. Italy Gene Therapy On Cardiovascular Disease Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 57. Asia-Pacific Gene Therapy On Cardiovascular Disease Sales Market Share by Type (2017-2028)

Figure 58. Asia-Pacific Gene Therapy On Cardiovascular Disease Sales Market Share by Application (2017-2028)

Figure 59. Asia-Pacific Gene Therapy On Cardiovascular Disease Revenue Market Share by Region (2017-2028)

Figure 60. China Gene Therapy On Cardiovascular Disease Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 61. Japan Gene Therapy On Cardiovascular Disease Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 62. South Korea Gene Therapy On Cardiovascular Disease Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 63. India Gene Therapy On Cardiovascular Disease Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 64. Southeast Asia Gene Therapy On Cardiovascular Disease Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 65. Australia Gene Therapy On Cardiovascular Disease Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 66. South America Gene Therapy On Cardiovascular Disease Sales Market Share by Type (2017-2028)

Figure 67. South America Gene Therapy On Cardiovascular Disease Sales Market Share by Application (2017-2028)

Figure 68. South America Gene Therapy On Cardiovascular Disease Revenue Market Share by Country (2017-2028)

Figure 69. Brazil Gene Therapy On Cardiovascular Disease Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 70. Argentina Gene Therapy On Cardiovascular Disease Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 71. Middle East and Africa Gene Therapy On Cardiovascular Disease Sales Market Share by Type (2017-2028)

Figure 72. Middle East and Africa Gene Therapy On Cardiovascular Disease Sales Market Share by Application (2017-2028)

Figure 73. Middle East and Africa Gene Therapy On Cardiovascular Disease Revenue Market Share by Country (2017-2028)

Figure 74. Turkey Gene Therapy On Cardiovascular Disease Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 75. Saudi Arabia Gene Therapy On Cardiovascular Disease Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 76. UAE Gene Therapy On Cardiovascular Disease Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 77. Methodology

Figure 78. Research Process and Data Source